Maha Aboul Ela, graduate of Faculty of Pharmacy, University of Alexandria, Egypt. Ph D in Pharmaceutical Sciences (Pharmacognosy) 1991, University of Alexandria-Egypt and Technical University of Berlin-Germany. She had done her Postdoctoral fellowship, from School of Pharmacy, University of London, UK. She is Member of the American Society of Pharmacognosy. She is also Member of the editorial board of many international scientifi c journals. Currently, she is head of department of Pharmaceutical Sciences, Faculty of Pharmacy, Beirut Arab University, Lebanon.She is Expert in QA in Higher Education. Research interest: Phytochemistry, Phytotherapy, discovering new drugs from natural sources and participation in drug development through applying different pharmaceutical approaches, more than 55 publications in the fi eld of phytochemistry, medicinal plants and phytotherapy.
Research interest: Phytochemistry, Phytotherapy, discovering new drugs from natural sources and participation in drug development through applying different pharmaceutical approaches, more than 55 publications in the fi eld of phytochemistry, medicinal plants and phytotherapy.
Mark Feitelson received his Ph.D. in Microbiology and Immunology in 1979 from the UCLA School of Medicine. He was an American Cancer Society postdoctoral fellow at Stanford University from 1980-82 and was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (Nobel laureate). In 1991, Dr. Feitelson became Associate Professor of Pathology and Cell Biology and head of the Molecular Diagnostics Lab in Microbiology at Thomas Jefferson University. In 2007, Dr. Feitelson moved to Temple University, where he is now Professor of Biology. His research has been supported by NIH, industry, and foundations for more than 35 years, has more than 140 publications and is presently head of the Professional Science Master’s program in Biotechnology at Temple University. Since 1980, his research interests have encompassed the pathogenesis of chronic hepatitis B infection and development of hepatocellular carcinoma on the cell and molecular levels. More recently, he co-founded the biotechnology start-up, SFA Therapeutics, which is developing anti-inflammatory and anti-tumor drugs from the gut microbiome.
Shinsuke Ifuku is a full professor of the Graduate School of Engineering, Tottori University, Japan. He graduated from the Kyoto University and received his Ph.D. of agriculture in 2005. Special attention is dedicated to the development of chitin nanofibers. Chitin nanofibers are fine nanofiber extracted from crab shell waste with 10 nm thick. Chitin nanofiber is a homogeneous water dispersion with efficient physical properties and fine nano-morphology. They showed abundant biological properties after skin or oral administrations. He established a venture company, with the name of MARINE NANOFIBER in 2016 to enhance the commercial application of the novel nanomaterial prepared from food waste.
Hiraku Onishi Education:
Bachelor: University of Tokyo (1980)
Master: University of Tokyo (1982)
Ph. D: Hoshi University (1989)
Associate Professor at Hoshi University (2002 - )
Visiting Researcher at the University of Texas at Austin (2003 – 2004)
Professor in Hoshi University (2010 - Till date)
Original paper (149), Review (16), Book (16), Patent (8), International Academic Meeting Presentation (34: Plenary lecture (6))
Nitin Chattopadhyay obtained his master’s in chemistry from Calcutta
University and Ph.D. from
Prof. Yoshiki Katayama has completed his Ph.D. from Kyushu University and worked in Dojindo laboratories Inc. Then he moved to Kyushu University as an associate professor in 1996 and became a professor in 2003. He is also a division head of Innovation Center of Advanced Medicine and Dean of Graduate School of System Life Sciences in Kyushu University and an Adjunct Professor in Chung Yuan Christian University in Taiwan. He received ”The Chemical Society of Japan Award for Creative Work” in 2016 and Japan Society of Analytical Chemistry Award in 2018. He has published more than 200 papers in reputed journals.
Professor Ambikanandan Misra is currently Professor and UGC-BSR Faculty Fellow at Faculty of Pharmacy, and former Dean, Faculty of Technology & Engineering (August 2011 to December 2015) & Head Department of Pharmacy (July 2003 to October 2008) at The Maharaja The Sayajirao University of Baroda. He has been associated with the field of pharmaceutical sciences for more than 39 years especially in the development of Novel Drug Delivery Systems. 47 Ph.D. and 136 Master students have completed their dissertation under his guidance. He has 7 books, 44 book chapters and 174 peer-reviewed publications in reputed journals. His citations are as on 27/06/2019 Scopus: (h-index 35, citations 4741) Google Scholar: (h-index 41, citations 6947).
Hirotomo Shibaguchi earned his Ph.D. degree in medicine from Nagasaki University School of Medicine in 1996. After working as a Postdoctoral Fellow at INSERM (France) and as a Research Fellow at Mayo Clinic Jacksonville (USA), he joined Department of Biochemistry, Faculty of Medicine, Fukuoka University in 2002, where he is currently an Associate Professor. He established sonodynamic therapy using low-intensity ultrasound in combination with a novel sonosensitizers. He investigated cancer gene therapy and/or immunotherapy using CEA-specific antibodies and scFv genes. He also started the development of a novel method for allergic diagnosis using a small amount of blood samples.
Dr. Dinesh Jaiswal is focused, dedicated and highly motivated professional with an unparalleled experience of more than 30 years in both the pharmaceutical industry and the academic settings. He is currently working as an independent consultant since June 2013 and supported a variety of projects and companies related to business development for API and drug product manufacturing in solids & parenteral.
After obtaining his B. Pharm, M. Pharm, and Ph.D. in Pharmaceutics from Banaras Hindu University, Varanasi, India, he has served as faculty in Institute of Technology, BHU, Varanasi, India, and as Scientist in various pharmaceutical industries such as Quad Pharmaceuticals, ISP/GAF, MOVA Pharmaceutical Corporation. In addition, he also worked in Forest Laboratories as Director, where he was responsible for the clinical supply coordination, the stability administration and contributed significantly to bring Lexapro, Linzess and Nemenda to market. Furthermore, he has made significant contributions by implementing new ideas, continuously motivating everyone, fostering a spirit of loyalty and always supporting the . and welfare of the
Shigeru Kurosawa received his B.E. and M.E. degrees from the Nagaoka University of Technology in 1984 and 1986, respectively, and a Ph.D. degree from Hokkaido University in 1990. Since 1990, he has been a researcher at National Institute of Advanced Industrial Science and Technology (AIST). His research interests are in analytical chemistry and polymer chemistry.